home / stock / blte / blte short
Short Information | Belite Bio Inc (NASDAQ:BLTE)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 272,263 |
Total Actual Volume | 1,542,877 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 13,613 |
Average Short Percentage | 17.33% |
Is there a BLTE Short Squeeze or Breakout about to happen?
See the BLTE Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-03-2024 | $45.6 | $45.75 | $46.24 | $45.14 | 24,454 | 4,553 | 18.62% |
07-02-2024 | $45.88 | $45.5 | $46.29 | $45.25 | 33,815 | 9,139 | 27.03% |
07-01-2024 | $45.9 | $45.82 | $45.98 | $45.26 | 15,818 | 1,880 | 11.89% |
06-28-2024 | $46.25 | $45.68 | $46.35 | $45.51 | 12,982 | 3,160 | 24.34% |
06-27-2024 | $47.48 | $46.5 | $47.69 | $46.295 | 28,706 | 3,517 | 12.25% |
06-26-2024 | $48.38 | $47.7 | $48.38 | $47.27 | 50,792 | 11,924 | 23.48% |
06-25-2024 | $48.5 | $48.5 | $48.85 | $48 | 159,247 | 37,472 | 23.53% |
06-24-2024 | $48.19 | $48.63 | $49.07 | $47.295 | 143,588 | 32,991 | 22.98% |
06-21-2024 | $48.65 | $48.5 | $48.7 | $45.01 | 314,741 | 54,964 | 17.46% |
06-20-2024 | $49.47 | $48.92 | $49.5 | $48.15 | 74,013 | 14,664 | 19.81% |
06-18-2024 | $49.39 | $49.65 | $49.7 | $48.83 | 55,084 | 7,333 | 13.31% |
06-17-2024 | $49.55 | $49.6 | $49.6 | $48.5001 | 52,277 | 6,974 | 13.34% |
06-14-2024 | $49.51 | $49.96 | $50.05 | $49.08 | 69,327 | 9,444 | 13.62% |
06-13-2024 | $49.8 | $50.1 | $50.15 | $49 | 102,178 | 13,061 | 12.78% |
06-12-2024 | $48.36 | $49.975 | $50 | $48 | 109,897 | 19,641 | 17.87% |
06-11-2024 | $48.53 | $48.8 | $48.95 | $48.02 | 28,740 | 3,465 | 12.06% |
06-10-2024 | $47.61 | $49.04 | $49.1 | $47.6 | 79,958 | 9,608 | 12.02% |
06-07-2024 | $47.78 | $48.47 | $48.6 | $47.23 | 90,482 | 9,564 | 10.57% |
06-06-2024 | $47.75 | $48.7 | $48.7 | $47.75 | 44,023 | 10,223 | 23.22% |
06-05-2024 | $48.5 | $48.69 | $48.8 | $47.245 | 52,755 | 8,686 | 16.46% |
News, Short Squeeze, Breakout and More Instantly...
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescent STGD1 ...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive ma...
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD) Data from a 24-month Phase 2 trial in adolescen...